Abstract
Certain psoriatic disease treatments, including tumor necrosis factor‐α inhibitors (TNFi), increase tuberculosis (TB) risk. Testing for latent TB infection (LTBI) before initiating systemic therapy has been standard practice for psoriasis (PsO) patients; however, updated consensus states routine testing is not required before initiating interleukin (IL)‐17 or IL‐23 inhibitors. This analysis reports safety outcomes in LTBI+ patients with moderate‐to‐severe PsO or active psoriatic arthritis (PsA) who received guselkumab for up to 5 years. Data were pooled from 11 phase 2/3 studies (7 PsO, 4 PsA). Guselkumab 100 mg was generally administered at Week 0, Week 4, then every 8 weeks (PsO studies) or every 4 or 8 weeks (PsA studies). Placebo‐randomized patients crossed over to guselkumab at Week 16 and Week 24 in PsO and PsA studies, respectively. Patients with active TB or a history of active TB were excluded. LTBI+ patients could participate if LTBI treatment was initiated before/with the first dose of study drug or if LTBI treatment was completed within 5 years before the first dose of study drug. Among 5 255 randomized patients, 374 (7.1%) had LTBI and received preventive treatment, most commonly isoniazid (82.1%) and rifampicin (11.8%). No new‐onset TB or LTBI reactivation occurred in any guselkumab‐treated patient. Through Year 1, liver transaminase elevations were more common in LTBI+ vs. LTBI− patients; ≤ 2% of LTBI+ patients had CTCAE Grade 3 elevations vs. 0.5% of LTBI− patients (no LTBI+ patients had Grade 4 elevations). From Year 1–5 (after ~98% of LTBI+ patients completed preventive treatment), transaminase elevations were generally similar among LTBI+ and LTBI− patients. The absence of observed TB risk in guselkumab‐treated patients suggests IL‐23 inhibitors may be better treatment options than TNFi in high‐risk patients, including those in TB‐endemic regions.
Funding Information
  • Johnson and Johnson

This publication has 15 references indexed in Scilit: